BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 37401266)

  • 1. SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy cells.
    Veldhoen M; Bertoletti A
    Immunol Cell Biol; 2023 Aug; 101(7):672. PubMed ID: 37401266
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
    Seekircher L; Bánki Z; Kimpel J; Rössler A; Schäfer H; Falkensammer B; Bante D; Forer L; Schönherr S; ; Harthaller T; Sacher M; Ower C; Tschiderer L; Ulmer H; Krammer F; von Laer D; Borena W; Willeit P
    Lancet Microbe; 2023 Aug; 4(8):e612-e621. PubMed ID: 37354911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
    Piñana JL; Vazquez L; Calabuig M; López-Corral L; Martin-Martin G; Villalon L; Sanz-Linares G; Conesa-Garcia V; Sanchez-Salinas A; Gago B; Facal A; Risco-Gálvez I; Olave MT; Espigado I; Lopez-Jimenez J; Hernández-Rivas JÁ; Avendaño-Pita A; Arroyo I; Ferrer E; García-Cadenas I; González-Santillana C; Roldán-Pérez A; Ferrer B; Guerreiro M; Suarez-Lledó M; Camara A; Campos-Beltrán D; Navarro D; Cedillo Á; Sureda A; Solano C; ; Martino R
    Blood Cancer J; 2023 Jan; 13(1):8. PubMed ID: 36599843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and Correlates of Breakthrough Infections With SARS-CoV-2.
    Yamal JM; Appana S; Wang M; Leon-Novelo L; Bakota E; Ye Y; Sharma S; Morrison AC; Marko D; Linder SH; Rector A; Jetelina KK; Boerwinkle E; de Oliveira Otto M
    Front Public Health; 2022; 10():856532. PubMed ID: 35619825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
    Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
    Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
    Piñana JL; López-Corral L; Martino R; Vazquez L; Pérez A; Martin-Martin G; Gago B; Sanz-Linares G; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; Corona M; Marcos-Corrales S; Tormo M; Hernández-Rivas JÁ; Montoro J; Rodriguez-Fernandez A; Risco-Gálvez I; Rodríguez-Belenguer P; Hernandez-Boluda JC; García-Cadenas I; Ruiz-García M; Muñoz-Bellido JL; Solano C; Cedillo Á; Sureda A; Navarro D;
    J Hematol Oncol; 2022 May; 15(1):54. PubMed ID: 35526045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
    Wei J; Matthews PC; Stoesser N; Newton JN; Diamond I; Studley R; Taylor N; Bell JI; Farrar J; Kolenchery J; Marsden BD; Hoosdally S; Jones EY; Stuart DI; Crook DW; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
    Nat Commun; 2023 May; 14(1):2799. PubMed ID: 37193713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers.
    Alishaq M; Nafady-Hego H; Jeremijenko A; Al Ajmi JA; Elgendy M; Vinoy S; Fareh SB; Veronica Plaatjies J; Nooh M; Alanzi N; Kaleeckal AH; Latif AN; Coyle P; Elgendy H; Abou-Samra AB; Butt AA
    PLoS One; 2021; 16(10):e0258820. PubMed ID: 34653228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses.
    Koutsakos M; Reynaldi A; Lee WS; Nguyen J; Amarasena T; Taiaroa G; Kinsella P; Liew KC; Tran T; Kent HE; Tan HX; Rowntree LC; Nguyen THO; Thomas PG; Kedzierska K; Petersen J; Rossjohn J; Williamson DA; Khoury D; Davenport MP; Kent SJ; Wheatley AK; Juno JA
    Immunity; 2023 Apr; 56(4):879-892.e4. PubMed ID: 36958334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
    Torres I; Bellido-Blasco JB; Gimeno C; Burgos JS; Albert E; Moya-Malo R; Gascó-Laborda JC; Tornero A; Soriano J; Meseguer-Ferrer N; Martínez-Serrano M; Ortíz-Rambla J; Buj H; Hernández N; Peiró S; Salas D; Limón R; Vanaclocha H; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Navarro D;
    J Med Virol; 2022 Aug; 94(8):3776-3782. PubMed ID: 35445415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
    J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.
    Zhu L; Mao N; Yi C; Simayi A; Feng J; Feng Y; He M; Ding S; Wang Y; Wang Y; Wei M; Hong J; Li C; Tian H; Zhou L; Peng J; Zhang S; Song C; Jin H; Zhu F; Xu W; Zhao J; Bao C
    Emerg Microbes Infect; 2023 Dec; 12(1):2146535. PubMed ID: 36373485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults.
    Nishimi K; Neylan TC; Bertenthal D; Seal KH; O'Donovan A
    JAMA Netw Open; 2022 Apr; 5(4):e227287. PubMed ID: 35420660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
    Bea S; Choi A; Kim JH; Cho YM; Choi WS; Jung J; Shin JY
    Diabetes Obes Metab; 2023 Sep; 25(9):2734-2742. PubMed ID: 37312652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
    J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
    Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
    J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.